Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of April 2023, specifically dated April 19, 2023. The report announces a strategic corporate action regarding the company's stock exchange listings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance and listing announcement rather than financial performance data.
Material Changes
- Voluntary Delisting: The Company announced its intention to voluntarily delist its Ordinary Shares from the Tel Aviv Stock Exchange (TASE).
- Exclusive Nasdaq Listing: Following the delisting, the Company's shares will trade exclusively on the Nasdaq Capital Market under the symbol "ICCM."
- Timeline: The last day of trading on the TASE is scheduled for July 20, 2023, with the official delisting date set for July 24, 2023.
- Share Transfer: All Ordinary Shares currently traded on the TASE may be transferred to Nasdaq.
Outlook, Risks, and Management Commentary
Management confirmed that the delisting in Israel will not affect the Company's continued listing on Nasdaq in the United States. The Company will continue to file public reports and make disclosures in accordance with U.S. SEC and Nasdaq rules. The filing incorporates by reference the "Forward-Looking Statements" section from the accompanying press release, though specific risk factors or contingencies are not detailed within the body of this Form 6-K text.
Investor Verification Checklist
- Verify the final trading date on the Tel Aviv Stock Exchange (July 20, 2023).
- Confirm the official delisting date from the TASE (July 24, 2023).
- Ensure the ticker symbol "ICCM" remains active on the Nasdaq Capital Market.
- Review the full press release (Exhibit 99.1) for detailed forward-looking statements and potential risks associated with the delisting process.